Biopharma | January 07, 2026
Medera doses final patient in high-dose HFpEF gene therapy trial
Heart failure affects an estimated 64.3 million people worldwide
Heart failure affects an estimated 64.3 million people worldwide
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
Subscribe To Our Newsletter & Stay Updated
